Comparative Pharmacology
Head-to-head clinical analysis: CYTOMEL versus UNITHROID.
Head-to-head clinical analysis: CYTOMEL versus UNITHROID.
CYTOMEL vs UNITHROID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liothyronine (T3) is a synthetic thyroid hormone that binds to thyroid hormone receptors in the nucleus, altering gene transcription and increasing basal metabolic rate, protein synthesis, and cardiovascular function.
Synthetic T4 (levothyroxine) is converted to T3, which binds to thyroid hormone receptors to regulate gene transcription, increasing basal metabolic rate.
Initial adult dose 25 mcg orally once daily; titrate by 12.5-25 mcg increments every 1-2 weeks based on TSH and clinical response. Usual maintenance dose 50-100 mcg once daily. Maximum dose 100 mcg daily.
Initial adult dose: 25-50 mcg orally once daily; titrate by 12.5-25 mcg every 4-6 weeks based on TSH; typical maintenance: 75-150 mcg orally once daily; maximum dose up to 300 mcg daily in severe hypothyroidism.
None Documented
None Documented
The terminal elimination half-life of liothyronine is approximately 1.0-2.5 days in euthyroid individuals, but may be prolonged in hypothyroidism (up to 3-4 days) and shortened in hyperthyroidism. Clinical context: This short half-life allows rapid dose titration and withdrawal for thyroid suppression tests.
6-7 days for L-thyroxine (T4) in euthyroid patients; prolonged to 9-10 days in hypothyroidism, shortened to 3-4 days in hyperthyroidism. Clinical context: once-daily dosing achieves steady state in 6-8 weeks.
Liothyronine (T3) is primarily eliminated by hepatic metabolism (deiodination and conjugation). Approximately 50-60% of a dose is excreted in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 20-30% via biliary elimination of conjugates.
Renal (approx. 20-40% as unchanged drug and glucuronide conjugates); fecal (minor, via bile).
Category C
Category C
Thyroid Hormone
Thyroid Hormone